An ATF3 Inducer Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease Through the AMPK and PKA Pathways
Ching-Feng Cheng, Ruey-Bing Yang, Wen-Ting Chen, Jia-Fang Chung, Hui-Chen Ku · 2025
Read An ATF3 Inducer Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease Through the AMPK and PKA Pathways by Ching-Feng Cheng, Ruey-Bing Yang, Wen-Ting Chen, Jia-Fang Chung, Hui-Chen Ku (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12732720.txt.
Description
Ching-Feng Cheng and co-authors published this liver study in 2025. Fatty liver tied to poor metabolism is spreading with obesity, and good drugs are scarce. The team tested a compound called ST32db, which switches on a gene named ATF3. They asked whether that switch could cut fat build-up in liver cells and in mice.
In dish-grown liver cells fed a fatty acid, the compound cut stored fat and muted genes that build fat. It also raised a gene for an enzyme that breaks fat down. In mice fed a rich diet for eighteen weeks, treated animals had lighter livers and less fat in the blood and liver. Two energy-sensing pathways in the liver ran hotter. The authors say the compound may shield the liver through those pathways.
Catalog record
| CREATOR | Ching-Feng Cheng, Ruey-Bing Yang, Wen-Ting Chen, Jia-Fang Chung, Hui-Chen Ku |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 23 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |